Abstract:
:Haploidentical hematopoietic stem cell transplantation (HSCT) using mismatched family member donors has historically been complicated by high rates of nonrelapse toxicity and the need for laboratory expertise in depleting grafts of T lymphocytes. Over the past decade, improvements in supportive care, the increased use of peripheral-blood stem cell grafts, and improved T-cell depletion techniques have reduced the incidence of graft failure and lowered the rate of nonrelapse mortality. In addition, clinical studies have demonstrated that the donor-recipient mismatch may be beneficial in this setting, stimulating an immunologic cell-mediated antileukemia effect that results in lower disease recurrence rates. All of these advances have led to improvements in outcomes following haploidentical HSCT, making it an attractive option available to some patients. Because most patients do not have a matched related donor available and time to identify an unrelated donor may be excessive, haploidentical HSCT is a potentially curative option for these patients.
journal_name
Curr Hematol Malig Repjournal_title
Current hematologic malignancy reportsauthors
Hale GAdoi
10.1007/s11899-007-0027-xsubject
Has Abstractpub_date
2007-07-01 00:00:00pages
202-7issue
3eissn
1558-8211issn
1558-822Xjournal_volume
2pub_type
杂志文章,评审abstract:PURPOSE OF REVIEW:The use of circulating tumor DNA (ctDNA) for the purposes of diagnosis, prognosis, assessment of treatment response, and monitoring for relapse is a new and developing field in lymphoma. This review aims to summarize many of the most recent advances in ctDNA applications. RECENT FINDINGS:Recent studi...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-018-0468-4
更新日期:2018-10-01 00:00:00
abstract::Patients with acute leukemia who undergo hematopoietic stem cell transplantation (HSCT) are susceptible to malnutrition caused by several factors including intensive cytotoxic therapy. This paper discusses the significance of malnutrition in these patients and provides an overview of nutrition therapy by the oral, ent...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-996-0007-6
更新日期:2006-09-01 00:00:00
abstract::The peripheral T cell lymphomas (PTCLs) are a heterogeneous group of neoplasms for which standardized treatment approaches remain elusive. A number of new therapeutic agents have become available, of which monoclonal antibodies (MAbs) represent a powerful tool for targeted treatment of PTCLs. Therapeutic MAbs vary in ...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-015-0290-1
更新日期:2015-12-01 00:00:00
abstract:PURPOSE OF REVIEW:The Choosing Wisely® initiative, led by the American Board of Internal Medicine Foundation in collaboration with national professional medical societies, aims to help patients choose care that is essential, free from harm, and evidence-based. The American Society of Hematology has advocated practices ...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-020-00593-2
更新日期:2020-08-01 00:00:00
abstract::Hodgkin's lymphoma (HL) is a relatively rare disease accounting for 15 % of all lymphoma. This disease has developed from an incurable disease to the adult malignancy with the most favorable prognosis. With current therapeutic approaches consisting of polychemo- and small-field radiotherapy, up to 80 % of all patients...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-015-0262-5
更新日期:2015-09-01 00:00:00
abstract::Chronic myeloid leukemia (CML) arises as a consequence of a chromosomal translocation giving rise to the Philadelphia chromosome and Bcr-Abl oncogene. CML is a clonal disease of stem cell origin and an excellent example of a malignancy in which tumor-initiating cells may hold the key to disease eradication. The known ...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-010-0043-0
更新日期:2010-04-01 00:00:00
abstract::Advances in drug discovery have led to the use of effective targeted agents in the treatment of hematologic malignancies. Drugs such as proteasome inhibitors in multiple myeloma and tyrosine kinase inhibitors in chronic myeloid leukemia and non-Hodgkin lymphoma have changed the face of treatment of hematologic maligna...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-017-0369-y
更新日期:2017-06-01 00:00:00
abstract:PURPOSE OF REVIEW:Hematopoietic cell transplant (HCT) patients are required to have a caregiver present for up to 100 days post-transplant. Caregivers provide essential support during HCT but experience immense stress and burden. Increasing research has developed interventions for HCT caregivers. This review systematic...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-018-0445-y
更新日期:2018-06-01 00:00:00
abstract::Mantle cell lymphoma (MCL) is a unique lymphoma subtype comprising 6% to 8% of new lymphoma diagnoses. It is generally considered to be incurable with standard lymphoma therapies. The median overall survival (OS) is often reported to be 3 to 4 years, but more recent data suggest that the median OS may be longer than 5...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-009-0028-z
更新日期:2009-10-01 00:00:00
abstract::Although the majority of patients with acute myeloid leukemia (AML) achieve a complete remission with induction chemotherapy, most will ultimately relapse. Therefore, the optimal postremission therapy for AML remains to be defined, and further improvements in treatment strategies are required. Clinical trials have dem...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-006-0021-8
更新日期:2006-06-01 00:00:00
abstract::In patients with acute leukemia, measurements of minimal residual disease (MRD) provide unique information on response to treatment. The most useful currently available MRD assays are polymerase chain reaction amplification of fusion transcripts and rearranged antigen-receptor genes and flow cytometric detection of ab...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章
doi:10.1007/s11899-008-0022-x
更新日期:2008-07-01 00:00:00
abstract::Mycosis fungoides (MF) and its leukemic variant, Sézary syndrome (SS), are malignancies of skin-homing T cells that comprise the majority of cutaneous T cell lymphomas (CTCL). Treatment of CTCL is limited and can be approached by skin-directed therapy or systemic therapy. Recent investigations into the pathogenesis of...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-015-0293-y
更新日期:2015-12-01 00:00:00
abstract::The prognosis value of interim positron emission tomography (PET) remains controversial in diffuse large B-cell lymphoma (DLBCL) patients because of the absence of consensus on criteria able to early identify good and bad responders to treatment. Visual interpretation using the International Harmonization Project (IHP...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-012-0129-y
更新日期:2012-09-01 00:00:00
abstract:PURPOSE OF REVIEW:Artificial intelligence (AI), and in particular its subcategory machine learning, is finding an increasing number of applications in medicine, driven in large part by an abundance of data and powerful, accessible tools that have made AI accessible to a larger circle of investigators. RECENT FINDINGS:...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-020-00575-4
更新日期:2020-06-01 00:00:00
abstract:PURPOSE OF REVIEW:Social media has dramatically changed the access and exchange of information in healthcare and beyond. A variety of platforms and resources exist allowing blood and marrow transplant providers, researchers, and patients to interact. We review the adoption of social media by the transplantation communi...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-018-0487-1
更新日期:2018-12-01 00:00:00
abstract::A high risk of arterial and venous thrombosis is the hallmark of chronic myeloproliferative neoplasms (MPNs), particularly polycythemia vera (PV) and essential thrombocythemia (ET). Clinical aspects, pathogenesis and management of thrombosis in MPN resemble those of other paradigmatic vascular diseases. The occurrence...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-013-0176-z
更新日期:2013-12-01 00:00:00
abstract::Primary mediastinal B-cell lymphoma (PMBCL) is a relatively rare lymphoma subtype affecting mainly young adults. Its molecular signature and clinical features resemble classical Hodgkin lymphoma. The optimal chemotherapy for this lymphoma subtype has not been established. The addition of rituximab to anthracycline bas...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章
doi:10.1007/s11899-014-0219-0
更新日期:2014-09-01 00:00:00
abstract::Multiple myeloma (MM) is characterized by abnormal proliferation of plasma cells in the bone marrow leading to symptoms of anemia, renal failure, hypercalcemia, and bone lesions. Bone imaging is critical for the diagnosis, staging, assessment for the presence and extent of bone lesions, and initial treatment of MM. Sk...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-017-0379-9
更新日期:2017-06-01 00:00:00
abstract:PURPOSE OF REVIEW:Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare malignancy derived from plasmacyoid dendritic cells whose biology, clinical features, and treatment options are increasingly better understood. RECENT FINDINGS:TCF4 is a master regulator that drives donwstream transcriptional programs in ...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-018-0489-z
更新日期:2018-12-01 00:00:00
abstract::Advances in chemotherapy administration have made acute lymphoblastic leukemia (ALL) a curable disease; however, most patients will relapse, despite readily attaining a complete remission. Treatment of relapse has shown dismal results with little advances made in the recent decades. Antigenic-directed therapy of ALL c...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-012-0120-7
更新日期:2012-06-01 00:00:00
abstract::The clonal blood disorders polycythemia vera, essential thrombocythemia and primary myelofibrosis belong to the BCR-ABL1-negative myeloproliferative neoplasms and are specified by increased production of terminally differentiated myeloid cells. Clonal evolution, disease initiation and progression are influenced by gen...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-013-0184-z
更新日期:2013-12-01 00:00:00
abstract::Chronic myelomonocytic leukemia is a clonal malignancy of the ageing hematopoietic stem cell characterized by a biased differentiation leading to persistent monocytosis and inconstant hypersensitivity of myeloid progenitors to granulo-monocyte colony-stimulating factor (GM-CSF). Cytogenetic abnormalities identified in...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-014-0225-2
更新日期:2014-12-01 00:00:00
abstract:PURPOSE OF REVIEW:The recent development of brentuximab vedotin (BV), an antibody-drug conjugate targeting CD30-positive cells, has led to therapeutic advances in the treatment of T cell lymphomas. In this review, we discuss key studies of BV in peripheral T cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL) and...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-020-00561-w
更新日期:2020-02-01 00:00:00
abstract::No therapy is uniformly effective in the management of immunoglobulin light chain amyloidosis (AL amyloidosis). Despite the common generalization, therapy is highly effective. Options available to patients with AL amyloidosis include high-dose therapy, but this is applicable to only about one fourth of patients. Thera...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-009-0013-6
更新日期:2009-04-01 00:00:00
abstract::Acute promyelocytic leukemia (APL) is characterized by coagulopathy, leukopenic presentation and sensitivity to anthracyclines, all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). For the last 25 years, APL has been treated with a combination of ATRA and chemotherapy for induction followed by consolidation and ...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-014-0205-6
更新日期:2014-06-01 00:00:00
abstract::Compared with acute lymphoblastic leukemia (ALL) in older children, ALL in infants has a dismal outcome because rearrangements of the mixed-lineage leukemia (MLL) gene occur in about 80% of these patients, leading to an aggressive type of leukemia. With most recent therapies, about 50% long-term event-free survival is...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-009-0023-4
更新日期:2009-07-01 00:00:00
abstract:PURPOSE OF REVIEW:Myelodysplastic syndrome (MDS) is a clinically and molecularly heterogeneous disease, which primarily occurs in older adults. Although hypomethylating agents have survival benefit and are the current standard of care, many MDS patients will not garner a response from therapy. For those who do respond,...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-018-0477-3
更新日期:2018-12-01 00:00:00
abstract::Myeloproliferative neoplasms (MPNs) are stem cell-derived clonal myeloid malignancies characterized by a unique somatic mutational profile since three mutually exclusive mutations (JAK2V617F, MPL, and CALR) sustain the great majority of the cases. However, clinical observation that autoimmune diseases may predispose t...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-014-0227-0
更新日期:2014-12-01 00:00:00
abstract::Follicular lymphoma (FL), the most common indolent lymphoma, typically presents in advanced-stage disease. Currently available therapy does not generally result in a curative outcome, but survival in FL has improved since the introduction of anti-CD20 monoclonal antibody immunotherapy. The goals of treatment include p...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-011-0099-5
更新日期:2011-12-01 00:00:00
abstract::BCR-ABL-negative myeloproliferative neoplasms include primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Clonal stem cell proliferation and dysregulated JAK/STAT molecular pathways characterize these hematologic malignancies. Symptoms experienced by patients are heterogeneous including excessive ...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-014-0239-9
更新日期:2014-12-01 00:00:00